Syngene Acquires Biologics Manufacturing Facility from Emergent BioSolutions Inc. for USD 36.5 Million
Syngene International Limited, a leading integrated research, development, and manufacturing services company, has announced the conclusion of the acquisition of a state-of-the-art biologics facility from Emergent Manufacturing Operations Baltimore, LLC, a subsidiary of Emergent BioSolutions Inc. The facility, acquired by Syngene USA Inc., a wholly owned subsidiary of Syngene, is fitted with multiple monoclonal antibody (mAbs) manufacturing lines and was acquired at a gross value of USD 36.5 million. This new site will increase Syngene’s total single-use bioreactor capacity to 50,000L for large molecule discovery, development, and manufacturing services. It will also provide Syngene’s customers with continuity of supply from its four development and manufacturing facilities located in India and North America.
Key Highlights
- Syngene acquires its first biologics site in the USA from Emergent BioSolutions Inc.
- The acquisition includes a state-of-the-art biologics facility with multiple mAbs manufacturing lines.
- The facility was acquired at a gross value of USD 36.5 million by Syngene USA Inc.
- The new site will increase Syngene’s total single-use bioreactor capacity to 50,000L.
- The acquisition provides Syngene’s customers with continuity of supply from its four development and manufacturing facilities.